Antibody variable domains targeting the NKG2D receptor
AssigneeDragonfly Therapeutics, Inc.
InventorsGregory P. Chang, Ann F. Cheung, Asya Grinberg, William Haney, Bradley M. Lunde, Bianka Prinz
Life of this patent
Estimating the term…
Abstract
Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described. Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.
Claims14
An antigen-binding site that binds NKG2D, comprising an antibody heavy chain variable domain comprising a complementarity-determining region 1 (CDR1) sequence represented by the amino acid sequence of SEQ ID NO:48, a complementarity-determining region 2 (CDR2) sequence represented by the amino acid sequence of SEQ ID NO:30, and a complementarity-determining region 3 (CDR3) sequence represented by the amino acid sequence of SEQ ID NO:78, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:
- 80, or SEQ ID NO:82;
- and an antibody light chain variable domain comprising
- a CDR1 sequence identical to the amino acid sequence of SEQ ID NO:32, a CDR2 sequence identical to the amino acid sequence of SEQ ID NO:33, and a CDR3 sequence identical to the amino acid sequence of SEQ ID NO:34.
Dependencies are inferred from the claim text.